ASTX660

Phase 2Small molecule

AAstex Pharmaceuticals, Inc.

ASTX660 is one of 83 small molecule programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaTerminated

Advanced CancerActive, not recruiting

LymphomaPhase 2

Terminated

Advanced CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Zofran

Novartis

Preclinical

2 2

Cabenuva

GSK

Preclinical

1 3

ASTX660

AAstex Pharmaceuticals, Inc.

Phase 2

2 4

Nuvigil

NNuvo Research GmbH

Preclinical

1 5

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—6

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—7

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

1 9

PD-1 Monoclonal Antibody

SSichuan Baili Pharmaceutical Co., Ltd.

Preclinical

1 10

Immune Checkpoint Inhibitor

IImmuneSensor Therapeutics Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Advanced Cancer

NCT05082259

Q4 2027

Phase 1/2Active, not recruiting

Lymphoma

NCT02503423

Clinical

Trials by Indication[1]

Lymphoma2 trials

A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma

Terminated· Otsuka logo

Otsuka·Phase 1/2·NCT04362007·8 enrolled

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

Active, not recruiting· Taiho Oncology, Inc. logo

Taiho Oncology, Inc.·Phase 1/2·NCT02503423·253 enrolled

Single Dose1 trial

A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam

Completed·AAstex Pharmaceuticals, Inc.·Phase 1·NCT04411030·36 enrolled

Tics1 trial

Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers

Completed·AAstex Pharmaceuticals, Inc.·Phase 1·NCT04479800·21 enrolled

Acute Myeloid Leukemia1 trial

A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Terminated·AAstex Pharmaceuticals, Inc.·Phase 1·NCT04155580·68 enrolled

Advanced Cancer1 trial

ASTEROID:A Phase I Trial of ASTX660 in Combination With Pembrolizumab in Patients With Solid Tumours: Utilizing Triple IAP Blockade as a Strategy to Maximize Immunogenic Cell Death and the Generation of an Efficient Adaptive Immune Response

Active, not recruiting·IInstitute of Cancer Research, United Kingdom·Phase 1·NCT05082259·61 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for ASTX660. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ASTX660 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ASTX660. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Astex Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAstex Pharmaceuticals, Inc.

ASTX660

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Trials by Indication[1]

Lymphoma2 trials

Single Dose1 trial

Tics1 trial

Acute Myeloid Leukemia1 trial

Advanced Cancer1 trial

References

Drug Info

Quick Facts

Related News